Several other brokerages have also recently commented on TRHC. Robert W. Baird cut Tabula Rasa HealthCare from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $24.00 to $11.00 in a research report on Tuesday, February 1st. Zacks Investment Research lowered Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. SVB Leerink lowered their price target on Tabula Rasa HealthCare from $23.00 to $11.00 and set a “market perform” rating on the stock in a research note on Monday, February 28th. Finally, Benchmark lowered their price target on Tabula Rasa HealthCare from $30.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, March 2nd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $14.53.
TRHC opened at $3.88 on Friday. Tabula Rasa HealthCare has a 12 month low of $2.77 and a 12 month high of $53.38. The stock has a market cap of $100.31 million, a P/E ratio of -1.04 and a beta of 1.55. The stock’s 50 day moving average price is $4.87 and its 200 day moving average price is $10.25. The company has a debt-to-equity ratio of 6.26, a current ratio of 1.22 and a quick ratio of 1.14.
In related news, Director Gordon Tunstall acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, March 1st. The shares were bought at an average cost of $5.50 per share, with a total value of $55,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis Helling bought 5,000 shares of Tabula Rasa HealthCare stock in a transaction dated Friday, March 4th. The stock was acquired at an average cost of $6.17 per share, for a total transaction of $30,850.00. The disclosure for this purchase can be found here. Insiders have acquired 17,000 shares of company stock worth $97,110 over the last ninety days. Company insiders own 10.20% of the company’s stock.
Institutional investors have recently modified their holdings of the business. First Trust Advisors LP boosted its stake in shares of Tabula Rasa HealthCare by 157.2% during the 4th quarter. First Trust Advisors LP now owns 3,467,436 shares of the company’s stock worth $52,012,000 after buying an additional 2,119,168 shares during the last quarter. State Street Corp increased its holdings in shares of Tabula Rasa HealthCare by 25.5% during the fourth quarter. State Street Corp now owns 864,578 shares of the company’s stock worth $12,969,000 after purchasing an additional 175,728 shares during the period. Legal & General Group Plc increased its holdings in shares of Tabula Rasa HealthCare by 107.0% during the fourth quarter. Legal & General Group Plc now owns 326,220 shares of the company’s stock worth $4,894,000 after purchasing an additional 168,592 shares during the period. Exchange Traded Concepts LLC increased its holdings in shares of Tabula Rasa HealthCare by 138.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 265,342 shares of the company’s stock worth $3,980,000 after purchasing an additional 154,159 shares during the period. Finally, Walleye Capital LLC bought a new position in shares of Tabula Rasa HealthCare during the fourth quarter worth approximately $2,274,000. Institutional investors own 89.38% of the company’s stock.
About Tabula Rasa HealthCare (Get Rating)
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.
- Get a free copy of the StockNews.com research report on Tabula Rasa HealthCare (TRHC)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.